<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934086</url>
  </required_header>
  <id_info>
    <org_study_id>BHV3000-401</org_study_id>
    <nct_id>NCT03934086</nct_id>
  </id_info>
  <brief_title>An Open-label, Intermediate Size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine</brief_title>
  <official_title>BHV3000-401: An Open-label, Intermediate-size, Expanded Access Study of BHV-3000 in the Acute Treatment of Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to allow subjects who completed any BHV3000 (rimegepant)
      clinical study to continue to have access to rimegepant while collecting ongoing safety data.

      (NOTE: ONLY FOR PATIENTS who participated in a previous BHV-3000/Rimegepant Clinical Trial in
      the past)
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Migraine</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rimegepant</intervention_name>
    <description>rimegepant 75 mg</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.Subjects who have completed any BHV3000 (rimegepant) clinical study without significant
        protocol violations.

        Exclusion Criteria:

          1. History of basilar migraine or hemiplegic migraine

          2. History with current evidence of uncontrolled, unstable or recently diagnosed
             cardiovascular disease

          3. HIV history

          4. Uncontrolled hypertension or uncontrolled diabetes

          5. Current diagnosis of major depression, other pain syndromes, psychiatric conditions
             (e.g., schizophrenia), dementia, or significant neurological disorders (other than
             migraine) that, in the Investigator's opinion, might interfere with study assessments

          6. History of gastric, or small intestinal surgery, or has a disease that causes
             malabsorption
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>April 29, 2019</study_first_submitted>
  <study_first_submitted_qc>April 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2019</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Migraine prevention, phonophobia, photophobia, nausea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

